Voriconazole as Prophylactic Therapy in Lung Transplant Recipients

Assessment of Safety and Efficacy of Voriconazole as Prophylactic Antifungal Therapy for Lung Transplant Recipients

Status

Terminated

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00455364

Acronym

VORI

Enrollment

Registered

2007-04-03

Start date

2007-04-30

Completion date

2007-04-30

Last updated

2013-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infection

Keywords

Fungal infection prophylaxis, Lung transplant, Fungal infection post lung transplant

Brief summary

The purpose of this study is to compare the safety and efficacy of Voriconazole with Itraconazole following lung transplantation.

Detailed description

All participants will receive itraconazole during their inpatient post transplant stay. As an outpatient, ten subjects will be randomized to receive itraconazole 200mg orally once daily for 6 month and ten patients to receive voriconazole 200mg orally twice daily for 6 months . All subjects will be followed in the clinic as per the standard transplant treatment

Interventions

DRUGVoriconazole

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Bilateral-lung or single-lung transplant recipients between the ages of 18- 65 years old. * Patients must be able to give informed consent prior to and again after transplantation

Exclusion criteria

* Lung transplant patients unable to give informed consent. * Prior adverse reaction to the drug itraconazole or voriconazole

Design outcomes

Primary

Measure	Time frame
Subject will be monitored for any fungal infection throughout the duration of the study.	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026